Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients

Canadian Journal of Gastroenterology

Volumn 21, Issue 10, 2007, Pages 637-642

  Mauro, Marina ^a   Radovic, Vladimir ^a   Armstrong, David ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bone mass; Crohn's disease; Infliximab; Osteopenia; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; INFLIXIMAB; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; ENZYME REPRESSION; FEMALE; HUMAN; LUMBAR SPINE; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; SEX RATIO;

EID: 36749042178     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/216162     Document Type: Article

References (37)

1. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-33.
2. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998;93:1483-90.
3. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease, Inflamm Bowel Dis 1998;4:268-75.
4. Martin JP, Tongue KA, Bhonsle U, Jacyna MR, Levi J. Bone mineral density in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:537-41.
5. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study. Gut 1997;40:313-19.
6. Bernstein CN, Blanchard JF, Leslie W, Wadja A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133:795-9.
7. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;46:176-81.
8. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease and ulcerative colitis: A nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002;156:1-10.
9. Siffledeen JS, Fedorak R, Siminoski K, et al. Bones and Crohn's: Risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 2004;10:220-8.
10. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002;8:87-92.
11. Bernstein CN, Blanchard JF, Metge C, Yogendron M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003;98:1797-801.
12. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: A population based cohort study. Gut 2004;53:251-5.
13. Andreassen H, Hylande E, Rix M. Gender, age and body weight are the major predictive factors for bone mineral density in Crohn's disease: A case-control cross-sectional study of 113 patients. Am J Gastroenterol 1999;94:824-8.
14. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn's disease on bone metabolism in vitro: A role for interleukin-6. J Bone Miner Res 2002;17:695-702.
15. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
16. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by highly sensitive immuno-PCR. Clin Chem 2001;47:1297-301.
17. Lanfranchi GA, Tragnone A. Serum and faecal tumor necrosis factor-alpha as marker of intestinal inflammation. Lancet 1992;339:1053.
18. Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-9.
19. Oelzner P, Franke S, Muller A, Hein G, Stein G. Relationship between soluble markers of inmune activation and bone turnover in postmenopausal woman with rheumatoid arthritis. Rheumatology (Oxford) 1999;38:841-7.
20. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001;276:563-8.
21. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
22. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNF-alpha potentially activates osteoclasts, through a direct action independent of any strongly synergistic with RANKL. Endocrinology 2002;143:1108-18.
23. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000;141:3956-64.
24. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomized trial. Lancet 2002;359:1541-9.
25. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
26. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004;20:607-14.
27. Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: A prospective study. Aliment Pharmacol Ther 2004;20:851-7.
28. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006;40:55-63.
29. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005;100:2031-5.
30. Mauro M, Armstrong D. Evaluation of densitometric bone-muscle relationships in Crohn's disease. Bone 2007;40:1610-4.
31. Mauro M, Armstrong D. Juvenile onset of Crohn's disease: A risk factor for reduced lumbar bone mass in premenopausal women. Bone 2007;40:1290-3.
32. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994;20:629-50.
33. Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998;43:2500-6.
34. Silvennoinen JA, Karttunen TJ, Niemela SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-6.
35. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396-403.
36. Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988;29:1332-6.
37. Bernstein CN, Leslie WD, LeBoff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124:795-841.